Skip links

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics!

Our platform for pre-targeted radioimmunotherapy is featured as the First Disclosure and cover story in this month’s AACR journal Molecular Cancer Therapeutics (MCT). Our innovative two-step regimen is set to revolutionize the delivery of radioactive payloads in cancer treatment. 

Discover more about our findings here: https://aacrjournals.org/mct/issue/23/9

Home